Claims for Patent: 9,144,585

Summary for Patent: 9,144,585

Title:	Isolated mesenchymal progenitor cells and extracellular matrix produced thereby
Abstract:	Provided are methods of isolating an extracellular matrix from mesenchymal progenitor cells which are characterized by a reduced differentiation ability into an adipogenic lineage as compared to adipose-derived mesenchymal stem cells. Also provide isolated extracellular matrix and hybrid devices comprising electrospun elements and extracellular matrix which can be used for various tissue regeneration, repair and reconstruction surgeries.
Inventor(s):	Itskovitz-Eldor; Joseph (Haifa, IL), Shtrichman; Ronit (Haifa, IL), Zussman; Eyal (Haifa, IL), Barak; Efrat (Nofit, IL)
Assignee:	Technion Research & Development Foundation Limited (Haifa, IL)
Application Number:	13/812,552
Patent Claims:	1. A method of isolating an extracellular matrix, comprising: (a) obtaining induced pluripotent stem cells (iPSCs) derived from plucked human hair follicle keratinocytes (HFKTs); (b) generating embryoid bodies (EBs) from said iPSCs; (c) generating single cells from adherent cells of said EBs, and (d) culturing said single cells in a culture medium which comprises ascorbic acid and does not comprise dexamethasone to thereby obtain a population of mesenchymal progenitor cells which comprises at least 70% CD105+ cells, wherein said mesenchymal progenitor cells exhibit at least 70% reduced differentiation potential into an adipogenic lineage as compared to differentiation of mesenchymal stem cells from an adult adipose source under identical assay conditions as analyzed after 28-30 days of culturing in a medium which comprises 10.sup.-6 M dexamethasone and indomethacin; and subsequently, (e) culturing said mesenchymal progenitor cells produced in step (d) under conditions which induce production of extracellular matrix from said mesenchymal progenitor cells, and subsequently, (f) isolating the extracellular matrix produced by said mesenchymal progenitor cells, thereby isolating the extracellular matrix. 2. The method of claim 1, further comprising decellularizing said extracellular matrix. 3. The method of claim 1, wherein said single cells from adherent cells of said EBs are obtained by: (a) dissociating the EBs to cell aggregates, (b) culturing said cell aggregates on a low-adhesive surface so as to select a population of adherent cells, and (c) dissociating said adherent cells to single cells. 4. The method of claim 1, wherein said EBs are 8-14 day-old human EBs. 5. The method of claim 3, wherein each of said aggregates comprises about 10-30 cells. 6. The method of claim 3, wherein said dissociating said EBs into said aggregates is effected using Collagenase B. 7. The method of claim 3, wherein said adherent cells are expanded by at least 2 fold within 2-3 days of culturing in said culture medium. 8. The method of claim 1, wherein differentiation into an osteogenic lineage of said mesenchymal progenitor cells is increased by at least 50% as compared to differentiation of mesenchymal stem cells from an adult adipose source under identical assay conditions. 9. The method of claim 1, wherein said culturing in step (e) is performed on an electrospun element. 10. The method of claim 1, wherein at least 70% of said population of mesenchymal progenitor cells are CD105+/CD90+. 11. The method of claim 1, wherein at least 70% of said population of mesenchymal progenitor cells are characterized by a CD105+/CD90+/CD73+/CD44+/CD29+ signature. 12. The method of claim 1, wherein at least 70% of said population of mesenchymal progenitor cells are characterized by a CD105+/CD45-/CD34- signature. 13. The method of claim 1, wherein said mesenchymal progenitor cells maintain the ability to form extracellular matrix for at least 8 passages. 14. The method of claim 1, wherein said culturing in step (d) is performed for 1-15 passages. 15. The method of claim 1, wherein said iPSCs are lentiviral vector-free iPSCs.

Details for Patent 9,144,585

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2030-07-27